NCT02930707

Brief Summary

Major abdominal surgeries are associated with severe abdominal pain, which can affect respiratory and cardiac functions, if insufficiently managed. This increases the incidence of post-operative morbidity. The objective of this study was to detect the efficacy and safety of magnesium sulphate as an adjuvant to the analgesia offered by local anesthetic in ultrasound guided TAP block in patients undergoing total abdominal hysterectomy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for phase_2 postoperative-pain

Timeline
Completed

Started Jan 2016

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 10, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 12, 2016

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

October 12, 2016

Status Verified

October 1, 2016

Enrollment Period

5 months

First QC Date

October 10, 2016

Last Update Submit

October 11, 2016

Conditions

Keywords

magnesium sulfatepostoperative painTAP blocktotal abdominal hysterectomy

Outcome Measures

Primary Outcomes (1)

  • total postoperative morphine consumption

    total amount of rescue morphine consumption in the first 24 hours postoperatively

    postoperative 24 hours

Secondary Outcomes (3)

  • postoperative pain

    postoperative 24 hours

  • first request of rescue analgesia

    postoperative 24 hours

  • side effects

    postoperative 24 hours

Study Arms (2)

Magnesium group

ACTIVE COMPARATOR

patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.

Drug: Magnesium Sulfate

control group

PLACEBO COMPARATOR

patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.

Drug: Bupivacaine

Interventions

ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.

Magnesium group

ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.

control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • weight: 50- 85 kg.
  • ASA score: I-III
  • scheduled for total abdominal hysterectomy

You may not qualify if:

  • history of relevant drug allergy.
  • coagulation disorders.
  • opioid dependence.
  • sepsis.
  • psychiatric illnesses that would interfere with perception and assessment of pain.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Abd-Elsalam KA, Fares KM, Mohamed MA, Mohamed MF, El-Rahman AMA, Tohamy MM. Efficacy of Magnesium Sulfate Added to Local Anesthetic in a Transversus Abdominis Plane Block for Analgesia Following Total Abdominal Hysterectomy: A Randomized Trial. Pain Physician. 2017 Nov;20(7):641-647.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Magnesium SulfateBupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Magnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia,ICU, and pain management

Study Record Dates

First Submitted

October 10, 2016

First Posted

October 12, 2016

Study Start

January 1, 2016

Primary Completion

June 1, 2016

Study Completion

November 1, 2016

Last Updated

October 12, 2016

Record last verified: 2016-10